Received Aug 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Shingles after first dose; is still experiencing PHN; did not complete the 2 dose series; This non-serious case was reported by a other health professional via call center representative and described the occurrence of shingles in a patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix and the did not receive 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced shingles (Verbatim: Shingles after first dose), post herpetic neuralgia (Verbatim: is still experiencing PHN) and incomplete course of vaccination (Verbatim: did not complete the 2 dose series). The outcome of the shingles was unknown and the outcome of the post herpetic neuralgia was not resolved and the outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the shingles and post herpetic neuralgia to be related to Shingrix. It was unknown if the company considered the shingles and post herpetic neuralgia to be related to Shingrix. Additional Information: GSK Receipt Date: 30-JUL-2025 The patient that received 1st dose of Shingrix in the past, did not complete the 2-dose series and the patient had a case of shingles and was still experiencing post herpetic neuralgia (PHN). The reporter asked should the patient receive a 2nd dose and if so, when was the best time to administer 2nd dose. Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.